Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Clinical dyslipidaemia is associated with changes in the lipid composition and inflammatory properties of apolipoprotein-B-containing lipoproteins from women with type 2 diabetes.

Ståhlman M, Pham HT, Adiels M, Mitchell TW, Blanksby SJ, Fagerberg B, Ekroos K, Borén J.

Diabetologia. 2012 Apr;55(4):1156-66. doi: 10.1007/s00125-011-2444-6. Epub 2012 Jan 18.

PMID:
22252473
2.

Increased lipolysis by secretory phospholipase A(2) group V of lipoproteins in diabetic dyslipidaemia.

Pettersson C, Fogelstrand L, Rosengren B, Ståhlman S, Hurt-Camejo E, Fagerberg B, Wiklund O.

J Intern Med. 2008 Aug;264(2):155-65. doi: 10.1111/j.1365-2796.2008.01932.x. Epub 2008 Feb 20.

3.

Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes.

Ouguerram K, Magot T, Zaïr Y, Marchini JS, Charbonnel B, Laouenan H, Krempf M.

J Pharmacol Exp Ther. 2003 Jul;306(1):332-7. Epub 2003 Apr 8.

4.

[Fatty acid composition and parameters of VLDL and LDL in persons with dyslipidemia].

Zák A, Zeman M, Tvrzická E, Stípek S, Buchtíková M, Pousek L, Nováková E.

Cas Lek Cesk. 2000 Jan 19;139(1):18-23. Czech.

PMID:
10750287
5.

Normal VLDL metabolism despite altered lipoprotein composition in type 1 diabetes mellitus.

Christ ER, Carroll PV, Albany E, Umpleby AM, Lumb PJ, Wierzbicki AS, Simpson HL, Sönksen PH, Russell-Ones DL.

Clin Endocrinol (Oxf). 2001 Dec;55(6):777-87.

PMID:
11895220
6.

Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM.

Taskinen MR, Packard CJ, Shepherd J.

Diabetes. 1990 Sep;39(9):1017-27.

PMID:
2200727
7.

Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study.

Duvillard L, Pont F, Florentin E, Galland-Jos C, Gambert P, Vergès B.

Eur J Clin Invest. 2000 Aug;30(8):685-94.

PMID:
10964160
8.

[Effect of fibrates on VLDL and LDL lipoprotein composition and parameters of their oxidation in hypertriglyceridemia].

Zeman M, Zák A, Tvrzická E, Konárková M, Stípek S.

Cas Lek Cesk. 2002 Apr 12;141(7):211-6. Czech.

PMID:
12053756
9.

Diabetic dyslipidaemia.

Adiels M, Olofsson SO, Taskinen MR, Borén J.

Curr Opin Lipidol. 2006 Jun;17(3):238-46. Review.

PMID:
16680028
10.

Diabetic dyslipidaemia: from basic research to clinical practice.

Taskinen MR.

Diabetologia. 2003 Jun;46(6):733-49. Epub 2003 May 28. Review.

PMID:
12774165
11.

The compositional abnormalities of lipoproteins in diabetic renal failure.

Attman PO, Knight-Gibson C, Tavella M, Samuelsson O, Alaupovic P.

Nephrol Dial Transplant. 1998 Nov;13(11):2833-41.

PMID:
9829487
13.
14.

ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan.

Hiukka A, Ståhlman M, Pettersson C, Levin M, Adiels M, Teneberg S, Leinonen ES, Hultén LM, Wiklund O, Oresic M, Olofsson SO, Taskinen MR, Ekroos K, Borén J.

Diabetes. 2009 Sep;58(9):2018-26. doi: 10.2337/db09-0206. Epub 2009 Jun 5.

15.
16.
17.

Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance.

Adiels M, Westerbacka J, Soro-Paavonen A, Häkkinen AM, Vehkavaara S, Caslake MJ, Packard C, Olofsson SO, Yki-Järvinen H, Taskinen MR, Borén J.

Diabetologia. 2007 Nov;50(11):2356-65. Epub 2007 Sep 12.

PMID:
17849096
19.

Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes.

Vergès B, Florentin E, Baillot-Rudoni S, Monier S, Petit JM, Rageot D, Gambert P, Duvillard L.

Diabetologia. 2008 Aug;51(8):1382-90. doi: 10.1007/s00125-008-1046-4. Epub 2008 Jun 5.

PMID:
18535816
20.

Supplemental Content

Support Center